Posts Tagged ‘biotechnology’

  ZS Associates, a global company that offers sales and marketing solutions to a variety of industries, has released its 2015 annual report, which takes a comprehensive look at how pharmaceutical companies are marketing to physicians. 

  We recently discussed how Oracle’s safety system has the ability to produce ad hoc descriptive statistical reports on quality data. This brings us to the last rule we’ll discuss in our “Argus Safety for CAPAs” blog series. 

  For several years, the FDA has been the center of scrutiny for not having an official social media policy available on its website. According to the Union of Concerned Scientists, the FDA was the only one of 17 government agencies not to have social media policy…until now. 

  The California Life Sciences Association released a new report that proves the Golden State, once again, is at the top of its game when it comes to life sciences. 

  We recently touched on how Argus Safety enables you to track product complaint data and follow it through resolution. Today, we’ll discuss another CAPA rule the safety system supports. 

  Presidential debates. Daraprim. Martin Shkreli. Drug pricing is what everyone’s talking about. Dr. Joshua P. Cohen, a research associate professor at the Tufts Center for the Study of Drug Development, wrote an excellent article that breaks down how drug prices are determined. He also shared some key facts that support the notion of the […]

  Over the last decade, the life sciences industry has gone from running clinical trials on paper or, in many cases, in Excel, to leveraging comprehensive web-based systems, such as electronic data capture (EDC) and clinical trial management systems (CTMS). But, in more recent years, the widespread use of mobile technology has enabled even more […]

  While we work in an industry in which we aim to treat patients, rich or poor, we live in a world where money is often deemed king. And, with an influx of financial investments pouring into newer pharmaceutical and biotechnology companies, people are jumping ship more than ever, making it harder for big pharma […]

Reading a recent LinkedIn Pulse post from Genentech’s VP of IT Americas, Cindy Elkins, made me smile. She said so many good things. Cindy discussed the IT landscape at the company, arguably the most famous biotech (ever!), and how the IT organization impacts employees and patients on many different levels. 

  Several months ago I posted Why Don’t I See Ads For Clinical Trials?, a piece in which I questioned just that. In a society where healthcare is always front and center, how is it that most of us are still unaware of our options when it comes to participating in clinical research? 

  Thanks to one of my LinkedIn contacts, I was introduced to a newly released “scorecard” that ranks pharmaceutical and biotechnology companies based on their precision medicine efforts. In essence, the organizations who made the cut are the ones moving precision medicine forward. They’re the ones focused on leveraging biomarkers to develop new therapies. 

  Academic research organizations (AROs) and academic medical centers (AMCs) are university-based institutions that conduct scientific research and play a vital role in the development of new drugs and medical devices. Historically, the majority of the research performed by AROs and AMCs has been funded by government divisions like the National Institutes of Health (NIH). […]